Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra L Zynger

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
International Journal of Surgical Pathology|January 14, 2026
Ovarian Thecal Metaplasia of the Adrenal Gland: A Contemporary Case Series With ImmunohistochemistryNatasha Santhanam, Debra L Zynger
Archives of Pathology & Laboratory Medicine|October 23, 2023
The Pathology Job Market Post-COVID-19-Where Are We Now? A Comparison of Pathology Job Advertisements From 2013-2017 to 2018-2022Debra L Zynger, Nat Pernick
Archives of Pathology & Laboratory Medicine|February 21, 2019
Understanding the Pathology Job Market: An Analysis of 2330 Pathology Job Advertisements From 2013 Through 2017Debra L Zynger, Nat Pernick
International Journal of Clinical and Experimental Pathology|January 23, 2009
High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancerDebra L Zynger, Ximing Yang
Human Pathology|April 26, 2017
HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?-replyZhaoying Xian, Debra L Zynger
American Journal of Clinical Pathology|April 29, 2016
Do Histopathologic Variables Affect the Reporting of Lymphovascular Invasion in Testicular Germ Cell Tumors?Bryce L French, Debra L Zynger
Human Pathology|September 29, 2015
Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotestingIan F Green, Debra L Zynger
The Breast Journal|March 3, 2018
HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DXGary H Tozbikian, Debra L Zynger
Human Pathology|November 24, 2018
A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancerGary H Tozbikian, Debra L Zynger
American Journal of Clinical Pathology|November 9, 2024
Factors impacting tumor displacement artifact and pseudo-lymphovascular invasion in testicular germ cell tumorsReem O Ahmed, Debra L Zynger
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
International Journal of Surgical Pathology|January 14, 2026
Ovarian Thecal Metaplasia of the Adrenal Gland: A Contemporary Case Series With ImmunohistochemistryNatasha Santhanam, Debra L Zynger
Archives of Pathology & Laboratory Medicine|October 23, 2023
The Pathology Job Market Post-COVID-19-Where Are We Now? A Comparison of Pathology Job Advertisements From 2013-2017 to 2018-2022Debra L Zynger, Nat Pernick
Archives of Pathology & Laboratory Medicine|February 21, 2019
Understanding the Pathology Job Market: An Analysis of 2330 Pathology Job Advertisements From 2013 Through 2017Debra L Zynger, Nat Pernick
International Journal of Clinical and Experimental Pathology|January 23, 2009
High-grade prostatic intraepithelial neoplasia of the prostate: the precursor lesion of prostate cancerDebra L Zynger, Ximing Yang
Human Pathology|April 26, 2017
HER2 loss after neoadjuvant treatment: is the adjuvant trastuzumab treatment feasible?-replyZhaoying Xian, Debra L Zynger
American Journal of Clinical Pathology|April 29, 2016
Do Histopathologic Variables Affect the Reporting of Lymphovascular Invasion in Testicular Germ Cell Tumors?Bryce L French, Debra L Zynger
Human Pathology|September 29, 2015
Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotestingIan F Green, Debra L Zynger
The Breast Journal|March 3, 2018
HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DXGary H Tozbikian, Debra L Zynger
Human Pathology|November 24, 2018
A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancerGary H Tozbikian, Debra L Zynger
American Journal of Clinical Pathology|November 9, 2024
Factors impacting tumor displacement artifact and pseudo-lymphovascular invasion in testicular germ cell tumorsReem O Ahmed, Debra L Zynger
Pageof 10